Skip to main content

ACR 2019 - Report from Day 3 (Tuesday)

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA

Hepatitis C-related cryoglobulinemic vasculitis 

Flares of vasculitis can still be a problem after hepatitis C-related cryoglobulinemic vasculitis patients are cured of their hepatitis C by direct-acting antivirals, as demonstrated by data from four registries presented at ACR 2019 in Atlanta, Georgia.

Herpes Zoster Vaccine Update

Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.

Autoinflammatory Diseases at the ACR Annual Meeting

It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.

ACR 2019 - Report from Day One (Sunday)

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

A Focus on WOCBA (Women of Childbearing Age)

Many rheumatic diseases affect women of childbearing age. In the age of biologic therapy, women are achieving better disease activity and there are increasing numbers of women with rheumatic diseases attempting pregnancy. 

A Review of the Review and How to Make the Information Stick

I have been attending the ACR Review Course for more than a decade, and it seems every year it gets better and better. Contrary to what most people think, this is not a board review course; it is more of a review of the latest research delivered by experts condensing rheumatology in eig

When Classification and Diagnosis Diverge

Like many rheumatologists who are headed to the 2019 American College of Rheumatology meeting in Atlanta, I am eagerly looking forward to learning about the new criteria in vasculitis, lupus, and autoinflammatory recurrent fevers. Yet conference attendees should remember that these crit

Tweets

Janet Pope Janetbirdope

7 months 3 weeks ago

Should we measure vit D in all pregnant women with SLE? As in general population low vitamin D increased miscarriage and preterm births. Weird as so did high vitamin D. Abstr 2531 #ACR #ACR19 @RheumNow #SLE #sle https://t.co/Mwb3WoCyBA

Janet Pope Janetbirdope

7 months 3 weeks ago

SLE uncommonly has ILD in clinical practice. 2% had ILD usually mild and non progressive abstr 1563 #ACR #ACR19 @RheumNow #SLE https://t.co/CWgdfEQZ27

Janet Pope Janetbirdope

7 months 3 weeks ago

Prednisone is associated with organ damage in SLE. Chicken or egg argument? Bad lupus gets more steroids and more damage AND steroids independently increase CV events and other damage ex OP and cataracts #ACR19 @RheumNow abstr 2562 #SLE https://t.co/onEII3OKhS

Janet Pope Janetbirdope

7 months 3 weeks ago

Are urine metabolomics able to differentiate between healthy controls (HC), RA, SLE, & SpA? Small study of prevalent pts showed SLE and RA metabolomics v diff from controls and SpA. Don't know if diff early or pre clinical disease #ACR19 @RheumNow abstr 2127 https://t.co/mBh5nxRcqk

David Liew drdavidliew

7 months 3 weeks ago

We know ovarian insuff with cyclophosphamide is dose-related, but in SLE data from @EmoryUniversity @emoryhealthcare the absolute numerical diff between success & failure is tighter than I imagined. Other factors at play? Also: time heals some wounds...

Dr Irwin Lim _connectedcare

7 months 3 weeks ago
Upadacitinib in AS Nice to the rapid response #ACR19 @rheumnow Abst2728 https://t.co/woAZbdb5QY

Jonathan Hausmann MD hausmannMD

7 months 3 weeks ago

25% of SLE and RA patients at this academic practice were receiving HCQ above recommended doses, by @SkorupaTara & @RobShmerling #ACR19 @rheumnow #Abstr #ACRBest https://t.co/pq379l9ZPH

Janet Pope Janetbirdope

7 months 3 weeks ago

SLE has high work disability. Interestingly work disability was not high in some organ systems such as renal but mild GN or CRF may not be symptomatic. Fibromyalgia, low education, low SED and older age increase work disability ACR219 @RheumNow abstr 1578 https://t.co/DdHgluRPIV

Mike Putman EBRheum

7 months 3 weeks ago

TULIP1 Anifrolumab RCT in SLE Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS) Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6) Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed.

Mike Putman EBRheum

7 months 3 weeks ago

So much JAKi right now - RA, PsA, SLE, and more! Last tweet of the day. Curious to hear... Which JAKi do you think will win the JAK-wars? @RheumNow

×